Prolonged dexamethasone cuts delayed nausea after chemo

Prolonged dexamethasone cuts delayed nausea after chemo
Adding dexamethasone to prochlorperazine on days two and three, following palonosetron and dexamethasone on day one, reduces delayed nausea in patients receiving chemotherapy containing a platinum-based drug or an anthracycline, according to research published online Aug. 20 in the Journal of Clinical Oncology.

(HealthDay) -- Adding dexamethasone to prochlorperazine on days two and three, following palonosetron and dexamethasone on day one, reduces delayed nausea (DN) in patients receiving chemotherapy containing a platinum-based drug or an anthracycline, according to research published online Aug. 20 in the Journal of Clinical Oncology.

Joseph A. Roscoe, Ph.D., of the University of Rochester in New York, and colleagues conducted a randomized, double-blind study of the effectiveness of several for the prevention of DN: palonosetron plus dexamethasone followed by prochlorperazine; granisetron plus dexamethasone followed by prochlorperazine; aprepitant plus palonosetron plus dexamethasone followed by aprepitant plus dexamethasone; or palonosetron plus dexamethasone followed by prochlorperazine plus dexamethasone.

The researchers observed no difference between the effects of palonosetron and granisetron on DN when given with dexamethasone on day one followed by prochlorperazine on days two and three. Also, aprepitant was no more effective at reducing DN than prochlorperazine. Some benefit was achieved, however, by adding dexamethasone to prochlorperazine on days two and three.

"Over half of the patients studied experienced DN, and control afforded by all of the antiemetic regimens examined was inadequate. The finding that a second-generation 5-hydroxytryptamine (5-HT RA), palonosetron, showed no greater efficacy in controlling DN than a first-generation 5-HT RA was disappointing," the authors write. "We were similarly disappointed that aprepitant provided no significant benefit over prochlorperazine in controlling DN. More effective regimens for controlling DN are needed and should include the addition of prolonged dexamethasone."

Two authors disclosed to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Chemo-induced nausea remains big problem, study says

Jun 02, 2011

A large, phase III study of four commonly used drug regimens to treat chemotherapy-induced nausea concluded that while two regimens were better at managing patients’ queasiness, none were totally effective – prompting ...

Multiple myeloma clinical trial closes early

Apr 05, 2007

Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose ...

Chemo combination promising for multiple myeloma

May 02, 2012

(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.